Physician profile
Lisa A Pullum
NPI 1063476604
$5,519.48
in general payments reported to CMS, 2019-2025
25 companies · $3,488 in 2025
The $3,488 reported for 2025 was more than what 87% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $64.96 · 2021: $85.97 · 2022: $375 · 2023: $368 · 2024: $761 · 2025: $3,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,842 · Food and Beverage: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,842.03 |
| Food and Beverage | $1,775.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $1,994.78 | 2025 | Evoke |
| Stryker Corporation | $1,412.99 | 2024-2025 | Mild Device Kit, Optablate, Spinejack |
| Boston Scientific Corporation | $592.25 | 2019-2025 | Intracept, General - Pain Management |
| Vertos Medical, INC. | $577.22 | 2019-2024 | Mild Device Kit |
| Abbott Laboratories | $156.01 | 2019-2025 | Proclaim |
| Medtronic, INC. | $135.83 | 2022-2025 | Intellis Adaptivestim, Vanta Adaptivestim, Synchromedii |
| Collegium Pharmaceutical, INC. | $75.71 | 2019-2023 | Xtampza |
| Globus Medical, INC. | $60.01 | 2025 | Senza |
| Novartis Pharmaceuticals Corporation | $58.48 | 2019-2020 | |
| Vertiflex, INC. | $57.98 | 2019 | |
| Nevro Corp. | $54.59 | 2019-2024 | Senza |
| Amgen INC. | $54.25 | 2019 | |
| Painteq LLC | $37.81 | 2023 | Painteq |
| Teva Pharmaceuticals USA, INC. | $37.54 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $30.72 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $27.57 | 2023 | |
| Abbvie INC. | $26.57 | 2023 | |
| Grt US Holding, INC. | $18.15 | 2022 | |
| Fidia Pharma USA INC. | $18.11 | 2022 | |
| Braintree Laboratories, INC. | $17.77 | 2020 | |
| Lilly USA, LLC | $17.76 | 2024 | Zepbound |
| Vertical Pharmaceuticals, LLC | $15.65 | 2019 | |
| Biodelivery Sciences International, INC. | $15.08 | 2021 | |
| Assertio Therapeutics, INC. | $14.58 | 2019 | |
| Brainsway USA INC | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Pullum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.